Reece DE - Search Results

1

Bortezomib in multiple myeloma: a practice guideline.

Kouroukis CT, Baldassarre FG, Haynes AE, Imrie K, Reece DE, Cheung MC; Cancer Care Ontario Hematology Disease Site Group. Kouroukis CT, et al. Among authors: reece de. Clin Oncol (R Coll Radiol). 2014 Feb;26(2):110-9. doi: 10.1016/j.clon.2013.11.022. Epub 2013 Dec 8. Clin Oncol (R Coll Radiol). 2014. PMID: 24321107

2

Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.

Wechalekar AD, Chen CI, Sutton D, Reece D, Voralia M, Stewart AK. Wechalekar AD, et al. Leuk Lymphoma. 2003 Jul;44(7):1147-9. doi: 10.1080/1042819031000067918. Leuk Lymphoma. 2003. PMID: 12916866 Review.

3

Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60 years of age.

Reece DE, Bredeson C, Pérez WS, Jagannath S, Zhang MJ, Ballen KK, Elfenbein GJ, Freytes CO, Gale RP, Gertz MA, Gibson J, Giralt SA, Keating A, Kyle RA, Maharaj D, Marcellus D, McCarthy PL, Milone GA, Nimer SD, Pavlovsky S, To LB, Weisdorf DJ, Wiernik PH, Wingard JR, Vesole DH. Reece DE, et al. Bone Marrow Transplant. 2003 Dec;32(12):1135-43. doi: 10.1038/sj.bmt.1704288. Bone Marrow Transplant. 2003. PMID: 14647267 Review.

4

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Richardson PG, et al. N Engl J Med. 2005 Jun 16;352(24):2487-98. doi: 10.1056/NEJMoa043445. N Engl J Med. 2005. PMID: 15958804 Free article. Clinical Trial.

5

Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation.

Chang H, Qi XY, Samiee S, Yi QL, Chen C, Trudel S, Mikhael J, Reece D, Stewart AK. Chang H, et al. Bone Marrow Transplant. 2005 Nov;36(9):793-6. doi: 10.1038/sj.bmt.1705131. Bone Marrow Transplant. 2005. PMID: 16113669

6

Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.

Jaksic W, Trudel S, Chang H, Trieu Y, Qi X, Mikhael J, Reece D, Chen C, Stewart AK. Jaksic W, et al. J Clin Oncol. 2005 Oct 1;23(28):7069-73. doi: 10.1200/JCO.2005.17.129. Epub 2005 Aug 29. J Clin Oncol. 2005. PMID: 16129840

7

An update of the management of multiple myeloma: the changing landscape.

Reece DE. Reece DE. Hematology Am Soc Hematol Educ Program. 2005:353-9. doi: 10.1182/asheducation-2005.1.353. Hematology Am Soc Hematol Educ Program. 2005. PMID: 16304403

8

Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation.

Trieu Y, Trudel S, Pond GR, Mikhael J, Jaksic W, Reece DE, Chen CI, Stewart AK. Trieu Y, et al. Among authors: reece de. Mayo Clin Proc. 2005 Dec;80(12):1578-82. doi: 10.4065/80.12.1578. Mayo Clin Proc. 2005. PMID: 16342650

9

Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.

Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D. Chang H, et al. Leuk Res. 2007 Jun;31(6):779-82. doi: 10.1016/j.leukres.2006.08.002. Epub 2006 Sep 22. Leuk Res. 2007. PMID: 16996589

10

Management of multiple myeloma: the changing landscape.

Reece DE. Reece DE. Blood Rev. 2007 Nov;21(6):301-14. doi: 10.1016/j.blre.2007.07.001. Epub 2007 Aug 29. Blood Rev. 2007. PMID: 17761373 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

265 results

Search Page